Hosted on MSN2mon
Loosening chimeric antigen receptor's grip on T-regulatory cells improves function, researchers find
A new paper from MUSC Hollings Cancer Center researchers is helping to reveal the "rules" for engineering chimeric antigen receptor (CAR) Tregs. Tregs, or T-regulatory cells, have shown promise in ...
The American Journal of Managed Care1d
Allogeneic vs Autologous CAR T-Cell Therapy Explained
Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...
Nature15d
PCR-mediated recombination: A general method applied to construct chimeric infectious molecular clones of plasma-derived HIV–1 RNA
You have full access to this article via your institution. To demonstrate the power of PCR–mediated recombination and provide an example of the general utility of the method, we constructed ...
The New England Journal of Medicine21d
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53
Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case ...
The American Journal of Managed Care5d
Geographic Barriers Impede Access to Novel Cancer Treatments
In the wake of novel bispecific and chimeric antigen receptor T-cell therapies for various cancers, geography still plays a big role in patients' abilities to receive such treatments.
The Facts12d
Restore Vision Announces First Patient Dosed in Phase I/II Clinical Trial of RV-001 for Gene-Agnostic Retinitis Pigmentosa
The first optogenetic "Chimeric Rhodopsin" gene therapy tested in humans.RV-001 starting dose was generally well tolerated in this open-label trial.RV-001 a gene-agnostic approach for RP patients.